CRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta Thalassemia

Human Gene TherapyVol. 34, No. 9-10 Gene Therapy BriefsCRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta ThalassemiaAlex PhilippidisAlex Philippidis*Correspondence: E-mail Address: [email protected]Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.Search for more papers by this authorPublished Online:17 May 2023https://doi.org/10.1089/hum.2023.29241.bfsAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 34Issue 9-10May 2023 InformationCopyright 2023, by Mary Ann Liebert, Inc., publishersTo cite this article:Alex Philippidis.CRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta Thalassemia.Human Gene Therapy.May 2023.341-344.http://doi.org/10.1089/hum.2023.29241.bfsPublished in Volume: 34 Issue 9-10: May 17, 2023PDF download